Merck & Co., Inc. (MRK) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $130.77 (+0.74%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 12, 2026 | Mohit Bansal | Wells Fargo | $150.00 | +14.7% |
| Feb 24, 2026 | Trung Huynh | RBC Capital | $142.00 | +8.6% |
| Feb 13, 2026 | James Shin | Deutsche Bank | $150.00 | +14.7% |
| Feb 4, 2026 | Asad Haider | Goldman Sachs | $133.00 | +1.7% |
| Dec 10, 2025 | Rajesh Kumar | HSBC | $120.00 | -8.2% |
| Dec 4, 2025 | Louise Chen | Scotiabank | $120.00 | -8.2% |
| Dec 2, 2025 | Asad Haider | Goldman Sachs | $120.00 | -8.2% |
| Nov 3, 2025 | Terence Flynn | Morgan Stanley | $100.00 | -23.5% |
| Sep 17, 2025 | Luisa Hector | Berenberg Bank | $90.00 | -31.2% |
| Jul 10, 2025 | Terence Flynn | Morgan Stanley | $98.00 | -25.1% |
| Apr 25, 2025 | Evan Seigerman | BMO Capital | $82.00 | -37.3% |
| Feb 5, 2025 | Terence Flynn | Morgan Stanley | $106.00 | -18.9% |
| Dec 2, 2024 | Courtney Breen | Bernstein | $110.00 | -15.9% |
| Nov 15, 2024 | Akash Tewari | Jefferies | $148.00 | +13.2% |
| Nov 1, 2024 | Evan David Seigerman | BMO Capital | $136.00 | +4.0% |
| Oct 9, 2024 | Trung Huynh | UBS | $136.00 | +4.0% |
| Oct 7, 2024 | Carter Gould | Barclays | $140.00 | +7.1% |
| Aug 15, 2024 | Akash Tewari | Jefferies | $147.00 | +12.4% |
| Jul 31, 2024 | Colin Bristow | UBS | $142.00 | +8.6% |
| Jul 31, 2024 | Geoff Meacham | Bank of America Securities | $145.00 | +10.9% |
Top Analysts Covering MRK
MRK vs Sector & Market
| Metric | MRK | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.29 | 2.25 | 2.42 |
| Analyst Count | 21 | 8 | 19 |
| Target Upside | +6.7% | +16316.2% | +17.1% |
| P/E Ratio | 36.84 | 2.98 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $17.26B | $17.57B | $17.85B | 4 |
| 2026-12-31 | $16.62B | $16.92B | $17.20B | 8 |
| 2027-03-31 | $16.49B | $16.79B | $17.06B | 4 |
| 2027-06-30 | $17.04B | $17.35B | $17.63B | 4 |
| 2027-09-30 | $18.54B | $18.88B | $19.18B | 5 |
| 2027-12-31 | $18.29B | $18.62B | $18.92B | 4 |
| 2028-12-31 | $74.78B | $74.80B | $74.82B | 18 |
| 2029-12-31 | $72.75B | $74.33B | $75.57B | 11 |
| 2030-12-31 | $72.33B | $73.90B | $75.14B | 9 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $2.35 | $2.41 | $2.46 | 7 |
| 2026-12-31 | $2.06 | $2.11 | $2.16 | 4 |
| 2027-03-31 | $2.06 | $2.11 | $2.15 | 4 |
| 2027-06-30 | $2.22 | $2.27 | $2.32 | 5 |
| 2027-09-30 | $2.60 | $2.66 | $2.71 | 8 |
| 2027-12-31 | $2.43 | $2.49 | $2.55 | 4 |
| 2028-12-31 | $8.90 | $10.72 | $13.20 | 8 |
| 2029-12-31 | $10.12 | $10.40 | $10.63 | 6 |
| 2030-12-31 | $9.84 | $10.12 | $10.34 | 6 |
Frequently Asked Questions
What is the analyst consensus for MRK?
The consensus among 21 analysts covering Merck & Co., Inc. (MRK) is Buy with an average price target of $131.58.
What is the highest price target for MRK?
The highest price target for MRK is $150.00, set by Mohit Bansal at Wells Fargo on 2026-03-12.
What is the lowest price target for MRK?
The lowest price target for MRK is $76.00, set by Colin Bristow at UBS on 2021-12-13.
How many analysts cover MRK?
21 analysts have issued ratings for Merck & Co., Inc. in the past 12 months.
Is MRK a buy or sell right now?
Based on 21 analyst ratings, MRK has a consensus rating of Buy (2.29/5) with a +6.7% upside to the consensus target of $131.58.
What are the earnings estimates for MRK?
Analysts estimate MRK will report EPS of $2.41 for the period ending 2026-09-30, with revenue estimated at $17.57B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.